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Abstract (250 words) (Background, aims, results, conclusions) 
 
Human zinc-α2-glycoprotein (ZAG) is a 42 kDa adipokine which regulates body fat mass and 
is associated with cachexia and obesity. ZAG belongs to the major histocompatibility 
complex class I protein family and binds long chain polyunsaturated fatty acids in its groove 
formed from the α1 and α2 domains. To identify the molecular basis of its lipid-binding 
function, we determined the first crystal structure at 2.49Å resolution for fatty acid-bound 
ZAG, where the ligand was the fluorescent 11-(dansylamino)undecanoic acid (DAUDA). The 
192 kDa crystallographic asymmetric unit contained six ZAG and eight fatty acid molecules 
in unique conformations. Six fatty acid molecules were localised to the ZAG grooves, where 
its tails were bound in two distinct conformations. The carboxylate groups of three fatty acids 
projected out of the groove, while the fourth was hydrogen bonded with R73 inside the 
groove. Other ligand-residue contacts were primarily hydrophobic. A new fatty acid site was 
revealed for two further DAUDA molecules at the ZAG α3 domains. Following 
conformational changes from unbound ZAG, the α3 domains formed tetrameric β-barrel 
structures lined by fatty acid molecules that doubled the binding capacity of ZAG. Analytical 
ultracentrifugation revealed that ZAG in solution was a monomer in the absence of DAUDA, 
but formed small amounts of tetramers with DAUDA. By showing that ZAG binds fatty acids 
in different locations, we demonstrate an augmented mechanism for fatty acid binding in 
ZAG that is distinct from other known fatty acid binding proteins, and may be relevant to 
cachexia.  
 
Summary statement (40 words): The first crystal structure for fatty acid-bound zinc-α2-
glycoprotein revealed fatty acid binding in its main groove formed by its α1 and α2 domains, 
and a further fatty acid binding site within a tetramer of α3 domains. 
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INTRODUCTION 
Zinc-α2-glycoprotein (ZAG) is a 42 kDa adipokine first purified from human plasma by 
precipitation with zinc acetate [1]. ZAG has since been located in secretory epithelial cells 
and body fluids [2, 3]. ZAG is identical to a lipid mobilizing factor purified from the urine of 
patients with cancer cachexia and promotes lipolysis and browning of white adipose tissue [4, 
5]. Its expression in adipocytes is inversely related to body fat mass such that ZAG mRNA 
and protein expression are decreased in adipocytes from obese mice and patients [6, 7]. ZAG-
deficient mice increased body weight when fed a lipid rich diet [8] while the over expression 
of ZAG in ob/ob mice reduced body weight and white adipose tissue mass [9]. ZAG 
stimulates lipolysis through activation of the β3-adrenergic G-protein-coupled receptor in 
mice [10]. The dysregulation of ZAG in inflammatory disease [11-14] and cancer [15-18], 
including obesity and cachexia, continues to be re-emphasised together with its role in lipid 
metabolism.  
 
ZAG is a member of the major histocompatibility complex (MHC) class I protein family with 
α1, α2 and α3 domains. It is distinct from other members of this protein family in that the 
classic α1-α2 α-helical groove binds small hydrophobic molecules [19] rather than peptides, 
and the α3 domain associates with prolactin inducible protein rather than with β2 
microglobulin [20]. The original crystal structure of human plasma ZAG contained 
unresolved electron density in the α1-α2 groove at the same location where peptides 
classically bind to class I MHC proteins [21]. This density was later determined to be 
polyethylene glycol (PEG), a precipitant used for ZAG crystallisation [22]. Eleven conserved 
residues surrounded PEG in this crystal structure (F77, I76, Y14, R73, F101, Y161, Y154, 
Y117, W148, W134 and W115). These residues were hydrophobic with the exception of the 
positively charged R73. In other fatty acid binding proteins such as intracellular fatty acid 
binding proteins, an arginine residue anchors the negatively charged carboxyl group of fatty 
acids within otherwise hydrophobic binding sites [23]. Fluorescence displacement assays 
using 11-(dansylamino)undecanoic acid (DAUDA) revealed that the PEG and DAUDA 
binding sites were coincident and that ZAG preferentially binds polyunsaturated fatty acids 
[19, 22]. DAUDA is a saturated C11 fatty acid fluorescent probe with a dansyl group attached 
to its ω-methyl terminus (Figure 1C). DAUDA has been widely used in the characterization 
of fatty acid binding proteins from nematodes [24-26], schistosomes [27], human intracellular 
fatty acid binding proteins [28] and human serum albumin (HSA) [29, 30]. The location of 
the ZAG PEG/DAUDA binding site was confirmed by site-directed mutagenesis [31] which 
showed that Y14, F77, I76, Y154, Y161 and R73 were crucial for DAUDA binding. 
Recombinant Escherichia coli ZAG contained one tight and fifteen loose zinc binding sites 
[32], the latter thought to be responsible for the precipitation of ZAG from human plasma 
during its purification [1]. ZAG also bound the boron dipyrromethene fatty acid C16 
(BODIPY), and zinc caused ZAG to form oligomers to reduce BODIPY binding but not 
DAUDA binding [33]. These data indicated the presence of multiple fatty acid binding sites 
in the ZAG groove, similar to those seen in the structurally related CD1 immune proteins that 
bind bacterial lipids [34].  
 
The identity of ZAG’s physiological ligand remains unknown, yet this information is crucial 
to understanding the molecular basis of how ZAG regulates body fat mass. To clarify the 
mechanism of fatty acid binding to ZAG and how this relates to disease, we solved the crystal 
structure of ZAG in complex with the widely-used fatty acid derivative DAUDA, to 2.49Å 
resolution. To our knowledge, this represents the first crystal structure of a ZAG-fatty acid 
complex. This structure revealed two unique modes of lipid binding, one in a flexible groove 
between the ZAG α1-α2 domains, and the other inside a β-barrel formed by the self-
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association of four α3 domains. ZAG thus binds at least twice the expected amount of fatty 
acid than expected. The extent to which monomeric and tetrameric ZAG-DAUDA complexes 
were present in solution was examined using analytical ultracentrifugation (AUC). 
 
EXPERIMENTAL 
ZAG protein purification 
A pET23a clone containing human ZAG was expressed in E. coli BL21 (DE3) pLysE cells to 
produce protein inclusion bodies when induced with isopropyl β-D-1-thiogalactopyranoside. 
ZAG was purified from these inclusion bodies by refolding using 6 M guanidine 
hydrochloride and a hyper-dilution method as previously described [32]. Refolded ZAG was 
purified using a GE Superdex 75 size-exclusion chromatography column equilibrated with 
phosphate buffered saline (PBS; 2.7 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, 8 mM 
Na2HPO4) at a flow rate of 2 ml/min using an AKTA Pure and Unicorn software. Fractions 
corresponding to the ZAG elution peak were collected. The Superdex 75 column was 
calibrated using gel filtration standards (Bio-Rad, Hertfordshire, UK). The elution volumes 
(Ve) of each gel filtration standard and ZAG were used to calculate Kav values where Kav = Ve 
– V0 / Vc – V0 with a column volume (Vc) of 120 ml and a void volume (V0) of 44.9 ml. A 
graph of Kav against log10MW of the standard proteins was used to estimate the size of ZAG 
using its Kav value.  The purity of E. coli ZAG was confirmed by 4-20% non-denaturing 
gradient SDS PAGE. Purified ZAG was stored at -20°C before use in experiments. Prior to 
setting up crystallisations, ZAG was subjected to Superdex 75 size exclusion chromatography 
to remove any potential aggregates formed by freezing. Protein concentrations were 
determined using a Genesys 10uv scanning spectrophotometer (Thermo Electron 
Corporation), with a theoretical ε280 value of 71,071 cm-1 M-1 and a molecular mass of 32 276 
Da (calculated from the amino acid composition; [35]. Samples were dialysed against Hepes 
(4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid) - NaOH buffer pH ~7 when required. 
 
Fluorescence spectroscopy 
Fluorescence measurements were recorded at 22°C with a Perkin Elmer LS50B 
Luminescence Spectrometer using 2 ml samples in a quartz cuvette of path length 1 cm. The 
fluorescent fatty acid probe DAUDA (Thermo Fisher Scientific Technologies, Basingstoke, 
UK) was stored as a stock solution of ∼2 mg/ml in methanol in the dark at -20°C before being 
diluted into ethanol and then PBS or Hepes buffer. DAUDA concentrations were determined 
spectrophotometrically using ε335 = 4800 M-1 cm-1 in methanol as specified by the 
manufacturer. The fluorescence emission intensity of DAUDA was examined in PBS and 
Hepes buffer and upon sequential additions of ZAG (PBS and Hepes) and defatted human 
serum albumin (PBS; λex = 345 nm). Fatty acid-free albumin (Sigma. Dorset, UK) was 
reconstituted in PBS buffer prior to use in DAUDA titrations. The reconstituted albumin 
protein concentration was confirmed spectrophotometrically using ε335 = 38,553 M-1 cm-1. 
Fluorescence spectra were corrected for the effects of dilution. Solvent Raman scattering was 
corrected by subtracting the buffer-only spectrum from each individual spectra. The resulting 
titration curves were fitted using standard non-linear regression techniques to a single non-
competitive binding model to generate dissociation constant Kd values [32]. Results of 
competition experiments in which docosahexaenoic acid (DHA) was progressively added to a 
DAUDA:ZAG pre-formed complex were analysed using previously-reported expressions 
[36] to determine the apparent Ki value for DHA binding to ZAG. A stock solution of 1 mg / 
ml DHA in ethanol was diluted in PBS, and increasing concentrations of DHA were added to 
a mixture containing 0.9 µM DAUDA and 0.87 µM ZAG. 
 
Crystallization of ZAG complexes 
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Crystallization screens were performed with the hanging-drop vapour-diffusion method using 
24-well Linbro style plates (Molecular Dimensions Limited, Suffolk, UK). Individual crystals 
were cryoprotected in paratone:paraffin oil (50:50), and mounted using 0.1-0.2 mm 
CryoMount LithoLoops (Molecular Dimensions Limited, Suffolk, UK). Crystals were cooled 
to 100°K using a Cryostream (Oxford Cryosystems, Long Hanborough, UK) and screened for 
diffraction quality on an X8 Prospector (Bruker, Billerica, Massachusetts, USA) and then 
stored in 16-sample uni-pucks at 77°K in a cryogenic dewar prior to data collection. The 
strongest-diffracting crystals of ZAG-C11 DAUDA were grown using 2 µl ZAG:DAUDA (1: 
1.5) hanging drops. This was prepared from a 1 µl solution containing 310 µM ZAG and 460 
µM DAUDA in 16 mM Hepes, pH 7, 0.016% NaN3, 20% methanol which was mixed with 1 
µl of 1.3 M ammonium sulfate, 100 mM Hepes, pH 7.5. The buffer reservoir contained 1.3 M 
ammonium sulfate, 20 mM Hepes, pH 7.59. 
 
Crystallography data collection and processing 
X-ray diffraction data from ZAG-DAUDA crystals were collected at the Diamond Light 
Source (Didcot, UK) operating at 3 GeV in 900 electron bunch filling mode. Data were 
collected from the I02 and I03 beamlines at wavelengths of 0.9763 Å and 0.9795 Å 
respectively, and processed using Xia2 software. The strongest diffracting ZAG:DAUDA 
crystal was indexed in the I4 space group (Table 1). The quality of the MTZ reflection data 
were assessed using Phenix.xtriage [37] in which Matthew’s coefficient (Vm), the number of 
molecules in the asymmetric unit (Z), the twin fraction, twin law and twinning type were  
determined (Table 1). For molecular replacement, data from crystals in the I4 space group 
were detwinned using Detwin [38, 39] (CCP4), applying the relevant twin fraction and twin 
law (Table 1). The twinned data was used for refinement. 
 
Maximum-likelihood molecular replacement was performed using phaser-MR [37] (Phenix) 
using the α1-α2 domain of human ZAG as the search model (PDB ID: 1T7V, accessed from 
the PDB REDO database). The α3 domain was manually built using COOT followed by 
refinement cycles with Phenix refine and a twin law of –h, k, -l. The Grade web server was 
used to generate restraint files for DAUDA (Grade, version 1.2.9, 
http://www.globalphasing.com) and DAUDA molecules were fitted into positive electron 
density from composite omit maps generated using Phenix-refine.  Final refinement was 
performed with REFMAC 5.8 [40] with automatic twin refinement. The ZAG-DAUDA 
contacts were identified using LigPlot Plus software [41]. 
 
Analytical ultracentrifugation (AUC)  
AUC sedimentation velocity experiments were performed using multi-wavelength Optima 
and Proteome XL-I Beckman-Coulter instruments equipped with an An50Ti rotor, using cells 
with two-sector aluminium centrepieces at rotor speeds of 50,000 rpm at 20°C. Experiments 
on the Optima were performed with 6.2 µM ZAG in 20 mM Hepes buffer, pH 7.6 and PBS 
pH 7.4. Both samples were titrated with two C11 DAUDA at concentrations of 6.2 µM and 62 
µM. SEDFIT software (version 15.1) was used to analyse the absorbance data recorded at 
280 nm and 335 nm. The Lamm equation was directly fitted to every fifth boundary scan in a 
total of 112 scans in order to obtain the size distribution analysis c(s) that provided the 
sedimentation coefficient corrected to 20°C in water (s20,w) and molecular mass. The c(s) 
analyses were based on a fixed resolution of 200, minimum and maximum sedimentation 
coefficients (Smin and Smax) of 0.5 S and 15 S respectively, a frictional ratio of 1.2, a meniscus 
position of 6.2 cm, a cell bottom of 7.0 cm, a confidence level (F-ratio) of 0.95, a partial 
specific volume of 0.730 ml/g, buffer densities of 1.00543 g/ml and 0.99978 g/ml, and  buffer 
viscosities of 0.01002 cp and 0.01064 cp for PBS and Hepes respectively; all values being 
6 
 
calculated using SEDNTERP [42]. The baseline, meniscus and bottom of the cell were 
floated during fitting. The amounts of ZAG monomer and dimers were quantitated using the 
integration function in the c(s) analyses.  
 
Further sedimentation velocity experiments on the XL-I were carried out using high ZAG 
concentrations (155 µM ZAG) and upon addition of  DAUDA in ethanol (1:1.6) in 20 mM 
Hepes, 137mM NaCl, pH 7 and tracked using interference optics. The buffer densities of 
1.00575 g / cm3 (buffer) or 0.99106 g / cm3 (buffer with 9% ethanol) were determined using 
an Anton Paar DMA 5000 density meter. The viscosities of 0.010322 cP (buffer) or 0.013988 
cP (buffer with 9% ethanol) were determined using an Anton Paar Microviscometer AMVn.  
Interference data were analysed using SEDFIT software as described above except that every 
second boundary scan of a total of 80 (ZAG) or 100 (ZAG:DAUDA) scans were used.   
 
RESULTS  
ZAG purification and DAUDA binding affinity.  
In order to obtain the three dimensional structure of the ZAG:DAUDA complex, we first 
purified recombinant E. coli ZAG from inclusion bodies. As expected, refolded ZAG 
produced a single peak with an elution volume of approximately 88 ml on size exclusion 
chromatography corresponding to an estimated mass of 33.8 kDa (Figure 1A). Refolded and 
purified ZAG yielded a single band of approximately 32 kDa on 4–20% non-reducing SDS-
PAGE (Figure 1B). To confirm the affinity of ZAG for DAUDA, and compare this with that 
of HSA, DAUDA was titrated with increasing concentrations of ZAG in PBS and Hepes 
buffers, and likewise HSA in PBS buffer alone (Figure 2). The comparison of DAUDA 
binding to ZAG and HSA clarified the physiological function of ZAG. DAUDA has a low 
fluorescence emission intensity which becomes blue-shifted upon sequential additions of 
ZAG and HSA (Figures 2A-C). The spectral shifts are indicative of DAUDA binding at a 
hydrophobic binding site in both proteins and are accompanied by an increase in fluorescence 
emission intensity which was substantially greater for HSA than ZAG (Figures 2A-C). The 
DAUDA fluorescence emission wavelength shifted from 540 nm to 515 nm upon addition of 
ZAG (in both PBS and Hepes buffers) and to 490 nm upon addition of HSA. Notably, the 
shift upon addition of ZAG was less than that observed upon the addition of HSA. This 
suggested that the DAUDA binding site within ZAG was more solvent exposed than that of 
HSA. Assuming 1:1 binding in the fits, titrations of ZAG and HSA with DAUDA gave 
dissociation constants Kd of 0.11 ± 0.02 µM for the tightest of the DAUDA binding sites in 
HSA, 0.43 ± 0.15 µM for ZAG in PBS and 0.51 ± 0.04 µM for ZAG in 20 mM Hepes pH 
7.45 (Figure 2D). Our measurements indicated that ZAG bound DAUDA to a similar degree 
in the crystallisation (Hepes) and physiological buffers (PBS), and that HSA bound DAUDA 
more tightly than ZAG, making it likely that a physiological ligand of ZAG is a fatty acid.  
 
To show that the fluorescent dansyl group of DAUDA did not drive the ZAG:DAUDA 
interaction, a fluorescence competition experiment was performed. Consecutive additions of 
the untagged DHA to a pre-formed ZAG:DAUDA complex caused a reduction in the 
fluorescence emission intensity but no red shift in the fluorescence emission wavelength 
(Figure 2E). Notably the original DAUDA signal was not recovered despite the addition of 
excess ∼ 65 µM DHA to a ZAG:DAUDA complex with 0.9 µM DAUDA. Assuming 1:1 
ZAG:DAUDA binding and 1:1 ZAG:DHA binding, an apparent Ki of 10 µM was measured 
for the ZAG:DHA interaction (Figure 2F). 
 
Crystallisation of the ZAG:DAUDA complex.  
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Previous attempts to investigate the molecular basis of DAUDA binding to ZAG used pre-
formed ZAG crystals grown in the absence of PEG and soaked in 20 µM DAUDA. These 
crystals diffracted to 3 Å resolution and the DAUDA electron density could not be resolved 
[22]. Here, we followed an alternative route, in which a 1:1.5 ratio of ZAG to DAUDA in 
solution was crystallised in the absence of PEG using ammonium sulfate. Crystals of the 
ZAG-DAUDA complex were obtained in the tetragonal I4 space group with unit cell 
parameters a = b = 167.01 Å and c = 204.95 Å (Figure 1C, Table 1[43]). While the crystal 
and resulting dataset were twinned, the crystal structure was solved and refined to 2.49 Å 
resolution through molecular replacement (Methods). The electron density map revealed 
well-resolved features that corresponded to DAUDA ligand molecules.  
 
The crystallographic ZAG:DAUDA asymmetric unit contained six ZAG molecules 
positioned with their grooves opposing one another (Figure 3A). Intriguingly, the α3 domains 
of each ZAG:DAUDA complex moved by an angle of 25˚ towards the α2 helix of the ZAG 
groove when compared to the α3 domains in previously published apo-ZAG structures. This 
α3 movement enabled the formation of three 16-stranded β-barrel α3 tetramers within the 
crystal. In each tetramer, the classic DEBA β-sheets of the four immunoglobulin folds of the 
α3 domains were hydrogen-bonded to each other through the pairings of the outermost β-
strands D and A from adjacent β-sheets. Two of the tetramers were assembled from four 
chain A α3 domains (AAAA) and four chain B α3 domains (BBBB; Figure 3B). Both these 
tetramers were positioned on symmetry axes. The final tetramer was formed from the α3 
domains of chains CDEF and was not formed around a symmetry axis.  
 
The refined crystal structure revealed six clear areas of positive electron density in five ZAG 
molecules at or in the α1-α2 groove in the ZAG:DAUDA asymmetric unit. Even though the 
ZAG structure was solved to a higher resolution than previously, and this was extensively 
refined, this positive density was broken for regions of the fatty acid tails. There was a large 
positive peak consistent with the sulphur of the DAUDA sulphonyl group (Figure 1B). The 
remainder of the DAUDA molecule fitted well to the remaining areas of electron density 
(Figures 4A,B,C first column). Areas of positive electron density in the equivalent region of 
chain A were insufficient to support modelling of a DAUDA molecule, but were suggestive 
of DAUDA binding at low occupancy.  
 
Two distinct DAUDA binding sites were revealed in sufficient detail for a molecular 
interpretation. Six of eight DAUDA molecules were located close to or bound within the 
binding grooves of the α1-α2 domains in five ZAG chains B, C, D, E and F, leaving the 
single chain A empty. Four of these DAUDA were located in each of the grooves of four 
ZAG chains B, D, E and F while the remaining two DAUDA tethered the opposing α1-α2 
grooves of ZAG chains B and C to form a potential ZAG dimer (Figure 3A and Figures 6A-
C). Surprisingly a further two DAUDA molecules were bound to each of the α3 domains of 
ZAG chains A and B (Figure 3B and Figures 6A, B). These DAUDA molecules were located 
at the face of the four-stranded β-sheets of each α3 domain. This positioning meant that four 
DAUDA molecules were located inside each of the two chain A and chain B β-barrel ZAG 
tetramers (Figure 3B).  
 
Overall eight DAUDA molecules were contained within the ZAG:DAUDA asymmetric unit 
(Figure 3A), this being in good agreement with the 1:1.5 ZAG:DAUDA molar ratio used in 
co-crystallization. The ZAG:DAUDA asymmetric unit contained four groove-bound 
ZAG:DAUDA complexes (chains B, D, E and F), two groove-tethered DAUDA complexes 
(chains B and C), one empty ZAG α1-α2 binding groove (chain A), and two α3-bound 
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DAUDA molecules (chains A and B). This stoichiometry was in keeping with the ITC-
generated Kd value of 1.5 µM for ZAG:DAUDA binding [19] and our values of 0.43 µM and 
0.51 µM above (Figure 2). These Kd values were based on the assumption of one DAUDA 
binding site per ZAG. If multiple DAUDA binding sites exist on ZAG, as suggested by our 
crystal structure, ITC experiments would not have resolved these, and our Kd values will 
represent the tightest DAUDA binding site on ZAG. It is likely that DAUDA binds more 
strongly to the α1 - α2 groove than to the ZAG α3 domain.  
 
Movement of the ZAG α1-α2 groove.  
In order to examine each DAUDA groove binding site in more detail, pairs of ZAG chains E 
and F, B and C, and A and D were superimposed upon one another and pairwise root mean 
squared deviation (RMSD) comparisons were performed (Figures 4A-C, second column). An 
RSMD of 0.921 Å was observed for all ZAG atoms of chain B compared with chain C, 
suggesting a structural movement had occurred in one of these two ZAG chains. Chains E 
and F were similar, as were chains A and D, with lower average RSMD of 0.204 Å and 0.257 
Å respectively observed between all atoms in these pairs.  Notably, R73 of chain B moved 
dramatically compared with R73 of chain C, as did Y161, Y154 and R157 of the α2 helix in 
chain B which rotated outwards to open up the ZAG groove. Measurement of the distances 
across the ZAG grooves of all six ZAG molecules in the ZAG:DAUDA asymmetric unit 
showed that the distance across the groove of chain B was the largest at 23.0 Å compared to 
~20 Å for the other ZAG grooves (Table 2) including the previous ZAG:PEG structures [22, 
44]. The more open groove, trapped in one subunit of this crystal form, demonstrates that the 
binding groove can undergo large conformational changes which would allow it to 
accommodate larger molecules. 
 
Distinct DAUDA binding sites in the ZAG α1-α2 groove.  
The coordination of the six groove-associated DAUDA molecules with ZAG were examined 
using LIGPLOT analyses of the ligand-protein interactions.  
 
For the single DAUDA sites, the carboxylic head group of the DAUDA molecule occupying 
the ZAG groove of chain B formed two hydrogen bonds; one with R73 and the other with 
Thr169 (Figure 4A, third column, Figure 5). LIGPLOT showed that the rest of the DAUDA 
molecule made hydrophobic interactions with nonpolar atoms in Glu151, Trp148, Tyr117, 
Tyr154, Ile76, Cys166, Val153, Trp115, Tyr161, Phe101, Glu165 and Tyr12.  In keeping 
with the similarity of the protein structures of ZAG chains E, F, A and D, the positions of the 
three DAUDA molecules in chains E, F and D were almost identical, albeit different, to the 
co-ordination of DAUDA in chain B (Figures 4B and 4C, third column, Figure 5). In all three 
cases, the hydroxyl group of Tyr117 formed a hydrogen bond with the sulfonyl group of 
DAUDA, the naphthalene ring of DAUDA formed hydrophobic interactions with nonpolar 
atoms in R73, and the fatty acid tail adopted a bent conformation with the carboxylic head 
projected out of the groove (Figures 4B and 4C, fourth column, Figure 5). For ZAG chain E, 
Ile76, Phe77, Trp115 and Trp148 formed hydrophobic interactions with DAUDA. For ZAG 
chain F, the almost identical Ile76, Phe77, Phe101, Trp115 and Trp148 residues made 
hydrophobic interactions with DAUDA (Figures 4B, third column, Figure 5). For ZAG chain 
A, Ile76, Phe77, Phe101, Trp115 and Trp148, Gln65 and Tyr154 made similar hydrophobic 
contacts with DAUDA (Figure 4C, third column, Figure 5).  
 
For the two DAUDA molecules that tethered two ZAG grooves, the charged residues R73 
and R157 and the polar residue Tyr117 of ZAG chains B and C formed hydrogen bonds with 
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the sulfonyl groups and/or carboxylate tails of two DAUDA molecules which bridged 
between the two grooves due to their close proximity in the crystal (Figure 7F).  
 
Overall, our results show that ZAG binds DAUDA in two different conformations in the α1-
α2 groove, and also that DAUDA was localised in different regions within its groove. 
 
Oligomerisation of the ZAG:DAUDA complex in solution.  
To determine if DAUDA binding induced the formation of ZAG dimers and tetramers in 
solution, as suggested by the crystal structure, AUC was performed with ZAG in the absence 
and presence of DAUDA.  
 
Physiological concentrations of ZAG (6.2 μM) in the presence of 1:0, 1:1 and 1:10 molar 
ZAG:DAUDA equivalents were subjected to a high centrifugal force, and the sedimentation 
boundaries of each of ZAG and DAUDA were simultaneously but separately observed in real 
time at 280 nm (protein signal, Figure 8A,D) and 335 nm (DAUDA signal, Figures 8B,E) 
using the new multi wavelength absorbance optical system of the Optima AUC in phosphate 
buffered saline (PBS) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) 
buffers. PBS buffer was used to mimic physiological conditions while Hepes buffer was used 
to mimic the crystallisation conditions. The sedimentation boundaries were well fitted to size 
distribution analyses.   
(i) The resulting c(s) analyses for ZAG in the absence of DAUDA at 280 nm revealed 
a major ZAG monomer peak at a mean s20,w value of 2.65 ± 0.06 S in PBS and 2.90 ± 0.15 S 
in Hepes (black, Figures 8C,F), similar to our previous determination of 2.83 ± 0.02 S for 
apo-ZAG in 10 mM Hepes, 137 mM NaCl, pH 7.4 [33]. Mass distribution c(M) plots showed 
that the ZAG monomer peaks corresponded to mean molecular masses of 31,600 ± 1,100 Da 
in PBS and 31,000 ± 2,400 Da in PBS, which agreed well with the sequence-determined 
theoretical mass of 32,276 Da. No other peaks were observed. 
 (ii) Following the addition of DAUDA in PBS buffer, the monomer s20,w values were 
unaffected (Table 3, Figure 7C). In Hepes buffer, the monomer s20,w values were reduced 
upon addition of DAUDA (Table 3, Figure 8F), this being attributed to buffer density 
changes upon addition of DAUDA in ethanol. The s20,w values generated from the 
sedimentation boundaries at 335 nm in PBS and Hepes followed the sedimentation of 
DAUDA. Because these were within experimental error of those generated from the 
sedimentation boundaries at 280 nm for ZAG itself (Table 3), this showed that DAUDA was 
bound to ZAG. Low amounts of 0.5-5.3% of dimer (4.43 – 5.12 S, corresponding to 66,942 
Da) were seen for ZAG in the presence and absence of DAUDA (Figures 8C and 8F). 
However a small peak at 6.4 S was seen only in the presence of DAUDA at 335 nm (Figure 
8F, bottom panel) which corresponded to the mass of tetramer ZAG. Taken together, the data 
showed that DAUDA was bound to ZAG at physiological ZAG concentrations, and migrated 
with ZAG predominantly as a monomer in solution. The presence of small dimer and 
tetramer peaks in the presence of DAUDA indicated that ZAG dimers and tetramers are able 
to form in solution, as seen in the crystal structure.  
 
Higher concentrations of ZAG, equivalent to those used in the crystallization (155 µM ZAG; 
Figure 8G), in the presence of 1:1.6 molar ZAG:DAUDA equivalents were subjected to 
AUC, and the sedimentation of ZAG and DAUDA was observed in real time using 
interference optics (Figures 8G,H). The sedimentation boundaries were well fitted to give the 
c(s) analyses. Those for ZAG at high concentration revealed a ZAG monomer peak at a mean 
s20,w value of 2.69 ± 0.11 S in 20 mM Hepes pH 7.2 137 mM NaCl, similar to our 
observations at lower and more physiological ZAG concentrations. The intensity of the ZAG 
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monomer peak M was slightly increased by the addition of 248 μM (1:1.6) DAUDA (Figure 
8I). While the s value appeared to be reduced upon addition of DAUDA (blue, Figure 8I), 
corrections for large changes in the buffer viscosity and density showed that the s20,w value 
was unaffected by the addition of DAUDA (Table 3). More visible peaks D corresponding to 
2.3-3.6% dimeric ZAG, were apparent in the absence and presence of DAUDA. These 
support the existence in solution of the dimeric groove-tethered DAUDA complexes (chains 
B and C) seen in the crystal state. Lower amounts of 0.6-0.8% of ZAG corresponded 
approximately to trimer (5.8 S / 101 671 Da) and tetramer (6.4 S / 114 283 Da). The 
appearance of these small peaks makes it likely that these tetramers in solution constitute 
nucleation sites for lattice formation during crystallisation.  
 
DISCUSSION 
Here we report the first crystal structure of fatty acid binding to ZAG that revealed molecular 
details of multiple distinct and novel modes of lipid binding, namely within the ZAG α1-α2 
groove and its tetrameric α3 β-barrel (Figure 9A). By this work, we show that ZAG has 
increased its previously known number of fatty acid binding sites. These details for the 
classic DAUDA binding at the α1-α2 groove showed that R73, I76 and F77 form 
hydrophobic interactions in ZAG:DAUDA chains E and F with the single DAUDA site, 
while R73, I76, F77 and Y154 form hydrophobic interactions in ZAG:DAUDA chain D. R73 
forms a hydrogen bond, and I76, Y154, Y161 form hydrophobic interactions with 
ZAG:DAUDA chain B with the widened groove (Figure 7A). Interestingly, the α2-2 helix of 
ZAG (lower left helix, Figure 4A second column) moves in the complex, and not the α2-1 
helix (lower right helix, Figure 4A second column) that moves in classic MHC-antigen 
complexes. Our results distinguish the discrete fatty acid binding sites seen in ZAG from 
those seen in plasma HSA and intracellular FABP, as well as from MHC-peptide complexes. 
 
As a new observation relevant for ZAG function in solution, our ZAG:DAUDA crystal 
structure shows the ZAG α1-α2 groove of chain B has widened. The lipid binding immune 
class I MHC protein CD1e has a distance of 16 Å between groove helices, 2 Å wider than 
that of other CD1 family members [34]. CD1e is the only soluble member of the CD1 protein 
family. It binds two tailed bacterial lipids such as phosphatidylinositol and triacylated lipids 
and mediates lipid exchange/editing with CD1b [34]. The peptide binding immune class I 
MHC protein also contains a widened groove in the presence of bound peptide [45]. Its α2-1 
helix swings downwards on binding to open up the groove [45]. The widened groove is 
stabilised by interactions with bound chaperone TABP binding protein [45]. A wide and 
exposed lipid binding site in ZAG may therefore enable binding of larger lipids, enhance the 
rate of lipid exchange, and / or stabilise its interaction with its receptor. 
 
Our ZAG:DAUDA crystal structure confirmed our previous experiments that located the 
DAUDA binding site in the α1-α2 groove of ZAG. In these, fluorescence assays showed that 
PEG displaced bound DAUDA from the ZAG α1-α2 binding groove [22]. In agreement with 
this, our crystal structure showed that the positions of the DAUDA molecules in chains E, F 
and D overlapped with the positions of PEG seen in earlier ZAG crystal structures (Figure 
7E).  Furthermore, the three DAUDA molecules associated with ZAG chains E, F and D were 
each close to six residues R73, Y14, I76, F77, Y154 and Y161, that were previously 
identified using site directed mutagenesis to be critical for DAUDA binding by ZAG [31] 
(Figure 7B,C). This mutagenesis evidence supports our finding that the helices of the ZAG 
groove are flexible in solution, and enables the binding in solution of DAUDA in different 
locations and using different co-ordination geometries (Figure 7D).  
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LigPlot analyses showed that the dansyl group of DAUDA made variable amounts of 
hydrogen bonds and hydrophobic interactions with ZAG (Figure 5). In chain B, 33% of the 
DAUDA interactions arose from the dansyl group, while this increased to 63% for chain D, 
67% for chain E, 71% for chain F. For the α3 domain, 43% occurred for each of chain A and 
chain B. The Ki for DHA upon titration with a pre-formed ZAG:DAUDA complex yielded a 
Ki value of 10 µM, which was unexpectedly larger and weaker than the Kd value of 0.51 µM 
for DAUDA binding to ZAG. These Ki calculations assumed that the DAUDA and DHA 
binding to ZAG were reversible with 1:1 stoichiometries for ZAG. Notably addition of ∼ 60 
fold excess of DHA to ZAG:DAUDA did not completely displace all the DAUDA from 
ZAG. While the DAUDA fluorescence emission intensity decreased, it was not red shifted 
and did not return to that of the original DAUDA fluorescence emission (Figure 2F). This 
suggested DAUDA bound to another ZAG site that was unaffected by DHA, in keeping with 
the multiple binding sites for DAUDA in our ZAG:DAUDA crystal structure. Our Ki binding 
model therefore only estimated the affinity of DHA binding to ZAG to be in the µM range. 
Previous studies detected no changes in the fluorescence emission of dansylamide upon 
incubation with ZAG [19]. Despite the high totals of LigPlot interactions, the ability of DHA 
to displace DAUDA makes it unlikely that the dansyl group contributes significantly to 
DAUDA binding.  
 
For the novel observation of ZAG tetrameric α3 β-barrels, inspection showed that each was 
formed from four up-and-down four-stranded β-sheets stabilised by hydrogen bonds between 
the main chains at the edge of each β-sheets. Two of these bound four molecules of DAUDA 
in the unit cell (Figure 3B); these are evocative of the lipocalin fold which consists of an 
eight stranded antiparallel β-barrel enclosing an internal ligand-binding site [46]. Retinol, 
retinoic acid, arachidonic acid and steroids bind within the lipocalin fold. As such the 
lipocalins have been classified as extracellular transport proteins [46]. Our AUC analyses of 
ZAG in the absence and presence of DAUDA revealed that ZAG was predominantly a 
monomer in solution, but the detection of low amounts of tetramers (Figure 8) suggested that 
tetramers will form under the right conditions. The total buried surface area for each of the β-
barrels formed by the AAAA, BBBB and CDEF α3 chains (Figure 3B) at the tetramer 
interfaces was 1170 ± 30 Å2 per molecule (2340 Å2 in total). These values were in excess of 
800 Å2 per molecule, showing that the observed β-barrels are able to form a stable protein-
protein interaction in the right conditions [47]. Interestingly the DAUDA molecules do not 
bind to the α3 domain in the same place as the prolactin inducible protein (PIP) in its 
complex with ZAG [44].These DAUDA molecules were located at the four-stranded DEBA 
β-sheets of each α3 domain, formed from the β-strands D, E, B and A arranged in that order. 
Instead the β-strands D from each of the α3 domain and PIP form a hydrogen-bonded pair 
such that the two DEBA β-sheets form a continuous eight-stranded β-sheet to link the two 
proteins together. The ZAG-PIP complex does not therefore preclude formation of the ZAG-
DAUDA complex (Figure 9B). The recombinant E. coli ZAG used in our experiments is not 
glycosylated. The crystal structure of human plasma ZAG shows the presence of glycans at 
three positions, namely Asn89 and Asn108 on the α1-α2 groove and Asn239 on the α3 
domain (Figure 9C). Asn239 is conserved across species suggesting that glycosylation at this 
site may have a structural and or functional role. In the crystal structure of plasma ZAG, the 
glycan at Asn239 masks the DAUDA binding site in the α3 domain (Figure 9C). While the 
role of glycosylation in ZAG has not been directly tested in solution, this glycan chain in the 
α3 domain may be flexible enough to allow the binding of DAUDA to the α3 domain. 
 
Functionally, the ZAG tetrameric α3 β-barrels may relate to cachexia. In this context, the 
presence of extra fatty acid binding sites in ZAG tetramers may comprise a mechanism to 
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transport excess free fatty acids released from adipocytes during lipolysis to muscle for 
storage in lipid droplets. Cachexia is a disorder characterized by loss of skeletal muscle mass 
with or without adipose tissue depletion which cannot be reversed by calorific feeding [48]. 
Ultimately its consequences are detrimental and can be fatal [48]. Cachexia occurs in 
association with cancer and other non-cancerous diseases including heart failure, kidney 
disease, COPD [49]. In cachexia, white adipose tissue depletion results from lipolysis  and 
the generation of beige energy burning adipocytes [50]. Hyperlipidaemia is witnessed in 
patients with cancer cachexia [51, 52]. ZAG is upregulated in adipose tissue from human 
cachectic patients [53] and its expression correlates with circulating free fatty acid levels 
[12]Adipose tissue from mice bearing a cachexia inducing tumour showed shrunken 
adipocytes with modifications to the conformations of their cell membranes which contained 
excess mitochondria presumably to oxidise fatty acids [54]. However cachectic cancer 
patients also showed increases in amounts of lipids in their skeletal muscle compared with 
weight-stable cancer patients [55, 56]. Given that high plasma ZAG and fatty acid levels exist 
in cachexia, it is plausible that tetrameric ZAG may form to transport excess fatty acids 
released from adipocytes to muscle for storage in lipid droplets, thus contributing to adipose 
atrophy in cachexia. Further studies are required to determine the conditions in which ZAG 
tetramers form in solution and to clarify if DAUDA can bind to the ZAG α3 domain in 
solution. 
 
In comparison with other lipid-binding proteins, HSA is the main plasma buffer for fatty 
acids at concentrations one hundred fold greater (0.6 mM; [57]) than ZAG (6.2 µM; [58]). 
HSA contains seven fatty acid binding sites [59] and binds saturated, monounsaturated and 
polyunsaturated fatty acids with nM affinities (Kd) [60]. Nine intracellular fatty acid binding 
proteins (FABP1 - FABP9) are expressed in human tissues with high rates of fatty acid 
uptake and lipid metabolism [23]. With the exception of FABP1 the remaining FABP2-
FABP9 each have one fatty acid binding site, and bind saturated and unsaturated long-chain 
(≥ 14C) fatty acids with nM affinities [23]. FABP1 has two fatty acid binding sites and binds a 
range of hydrophobic compounds as well as fatty acids [23]. Our ZAG:DAUDA and 
HSA:DAUDA dissociation constants of 0.43 ± 0.15 µM (ZAG in PBS) and 0.51 ± 0.04 µM 
(ZAG in Hepes) and 0.11 ± 0.02 µM (HSA in PBS) are in keeping with previously reported 
measurements. Similar to HSA [30], FABP1 [61] and FABP2 [28], ZAG binds DAUDA with 
µM affinity [19, 31, 33] and within the range 0.08 µM to 1.5 µM (Table 4). The fact that 
ZAG binds DAUDA within a similar Kd range to HSA, FABP1 and FABP2 supports the 
likelihood that (one of) the physiological ligands of ZAG is a fatty acid. Polyunsaturated fatty 
acids (docosahexaenoic, eicosapentaenoic, linolenic, arachidonic and linoleic) were able to 
displace bound DAUDA from a preformed ZAG:DAUDA complex [19]. While we report an 
apparent dissociation constant (Ki) of 10 µM for DHA binding to a preformed ZAG:DAUDA 
complex here, the dissociation constants of ZAG for saturated, monounsaturated and 
polyunsaturated fatty acids (eicosapentaenoic, linolenic, arachidonic and linoleic) have yet to 
be measured. 
 
The two co-ordination geometries of DAUDA bound to the ZAG groove (Figure 7D) have 
been seen in the crystal structures of HSA and FABP2, as well as the projection of the fatty 
acid carboxylate head out of the fatty acid binding site. Similar to the co-ordination of 
DAUDA to ZAG chain B (Figure 7A), the crystal structure of DAUDA in complex with 
intracellular intestinal fatty acid binding protein (FABP2) shows the DAUDA carboxylate 
group formed hydrogen bonds with Arg106 and Trp82 at the bottom of the binding cavity 
[28]. The other co-ordination of DAUDA to ZAG (Figures 7B,C) is similar to the co-
ordinations of DAUDA to fatty acid binding sites 6 and 7 in HSA [29]. In both cases, a 
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positively charged amino acid (Lys212 in fatty acid binding site 6) and Arg218 (in site 7) 
interact with the DAUDA phenyl rings [29]. The projection of the fatty acid tail out of the 
groove and into the aqueous surroundings has been observed in oleate binding to human 
intracellular liver fatty acid binding protein (FABP1) [62] and in stearate binding by the 
immune MHC class I CD1c protein [63]. 
 
Overall we conclude that the observed multiple modes of fatty acid binding to a flexible α1-
α2 binding groove and to the α3 β-barrel (orange spheres, Figure 9A) may confer a unique 
role for ZAG for the transport of fatty acids and larger lipids to be delivered to tissues that is 
not possible with HSA. This may be relevant to cachexia.  
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TABLES 
 
Table 1. Crystallographic and refinement statistics for bacterial-expressed human ZAG 
complexed with C11 DAUDA as ligand 
Parameters Values 
Space group I4 
Unit cell dimensions (Å) a = b = 167.01Å; c = 204.95Å 
Matthews coefficient 3.70  
Data statistics  
Resolution (Å) 77.40 - 2.49  
Number of measurements  1,496,504  
Number of unique reflections  98,002  
Completeness (%)  100.0 (99.2) a 
Multiplicity of higher resolution shell 
Multiplicity of outer shell (2.53 – 2.49 Å) 
Overall multiplicity  
15.6 
15.6 
15.3  
Rpim (%) b 0.276 (1.205) 
(I)/σ(I)  
Half-set correlation CC(1/2) 
10.0 (1.0) 
0.995 (0.298) 
  
Refinement statistics b  
Rwork / Rfree (%) c 0.170 / 0.212 
Number of protein atoms 13792 
Number of water atoms 110 
Number of ligand atoms 240 
Number of reflections 95132 
Mean overall B value (Å2) 62.751 
Data used in refinement  
               Resolution range (Å2) 77.399 – 2.490 
               Percentage observed 99.980 
               Percentage of free reflections 2.758 
Root mean square deviations from ideal geometry   
              Bond lengths (Å) 0.55 
              Bond angles (degrees) 0.75 
Ramachandran plot  
               Number in favored regions (%) 92.5 
               Number in allowed regions (%) 7.3 
               Outliers (%) 
Twinning 
0.2 
0.637 for h, k, l 
0.363 for –h, k, -l 
  
 
a Values in parentheses are for the highest resolution shell. 
 
b Precision-indicating merging R factor, Rpim = Σh (1/(nh - 1))½  Σ1 | Ih1  - ˂Ih˃ | / Σh Σl ˂Ih˃, 
where nh is the number of observations of reflection h, Ihl is the lth observation of reflection h, 
and ˂Ih˃ is the average intensity for all observations l of reflection h. 
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c Rwork and Rfree = Σ || Fobs| - |Fcalc|| / Σ | Fobs | × 100  for 95% of the recorded data (Rwork) and 
5% of the data (Rfree). Fobs is the observed structure factor amplitude, and Fcalc is the 
calculated structure factor amplitude. 
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Table 2. Distance between the Cα atoms of the ZAG groove residues Asp75 on helix α1 
and Val153 on helix α2 
Polypeptide chain Separation distance (Å) 
  
ZAG chain A 20.9 
ZAG: DAUDA chain B 23.0 
ZAG chain C 20.1 
ZAG:DAUDA chain D 19.6 
ZAG:DAUDA chain E 20.3 
ZAG:DAUDA chain F 19.1 
ZAG:PEG (1T7V) 
ZAG:PEG (3ES6) 
20.5 
20.5 
 
 
 
 
Table 3. Sedimentation coefficients s20,w values for ZAG in the absence and presence of 
DAUDA 
  s20,w  
 PBS pH 7.4 (S) 20 mM Hepes pH 7.6 (S) 20 mM Hepes 137 
mM NaCl pH 7.2 
(S) 
ZAG:DAUDA 280 nm  335 nm   280 nm   335 nm  Interference   
1:0 2.65 ± 0.06   2.90 ± 0.15   2.69 ± 0.11 
1:1 2.57 ± 0.09 2.54 ± 0.29  2.58 ± 0.08  2.59 ± 0.38   
1:1.6     2.78 ± 0.10* 
1:10 2.64 ± 0.14 2.70 ± 0.07  2.69 ± 0.10 2.78 ± 0.31  
*Note this s20,w value does not correspond to the sedimentation coefficient (S) plotted in Figure 5I. 
The c(s) plot does not include corrections for buffer viscosity and density which were altered upon 
addition of DAUDA. DAUDA was added in 100% ethanol to give a final ethanol concentrations of 
9% in the sample cell. 9% ethanol was subsequently added to the buffer cell. 
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Table 4. Dissociation constants Kd for DAUDA binding to human extracellular and 
intracellular fatty acid binding proteins 
Protein Method Buffer n Kd (µM±SD) Reference 
ZAG ITC PBS 1 1.5 [19] 
ZAG Fluorescence PBS 1 0.73 ± 0.08  [31] 
ZAG Fluorescence 10 mM 
Hepes pH 
7.4 137 mM 
NaCl  
1 0.11 ± 0.01 [33] 
HSA Fluorescence 0.1M 
potassium 
phosphate 
pH 7.4 
3 0.08 [30] 
FABP2 Fluorescence 20 mM MES 
pH 5.5, 50 
mM NaCl 
1 0.3 [28] 
FABP2 ITC 20 mM 
Hepes pH 8, 
50 mM 
NaCl, 0.5 
mM EDTA), 
1.2 0.36 [28] 
FABP1 Fluorescence 10 mM Tris-
HCl pH 8 
* 0.17 ± 0.01  [61] 
Key: HSA, human serum albumin; FABP2, intestinal fatty acid binding protein; FABP1, liver 
fatty acid binding protein; n, number of binding sites; *, not disclosed 
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FIGURE LEGENDS 
 
Figure 1. Recombinant E.coli ZAG purification and crystals of the ZAG:DAUDA 
complex. A, Preparative size-exclusion chromatography of refolded ZAG in PBS buffer; 
(inset) Calibration of the Superdex 75 size exclusion gel filtration column using five standard 
proteins of known MW. ZAG had an elution volume of 88 ml generating a Kav value of 0.57 
and estimated MW of 33 787 Da (represented by the dotted line). B, Non-reducing gradient 4 
– 20% SDS PAGE of 22 μM, 11 μM and 4.4 μM ZAG. C, Chemical structure of the 
dansylated fluorescent C11 fatty acid probe 11-(dansylamino)undecanoic acid (DAUDA). The 
fatty acid carboxylate group is highlighted in red, the fatty acid carbon chain is highlighted in 
green, the dansyl sulfonyl group is highlighted in blue and the dansyl napthalene group is 
highlighted in dark blue. DAUDA has a maximum absorbance wavelength of 335 nm. D, 
Crystals of the ZAG:DAUDA complex used for the structure determination. Crystals were 
prepared using a 2 µl hanging drop containing 155 µM ZAG, 230 µM DAUDA (1:1.5 
ZAG:DAUDA), 10% methanol (v/v), 58 mM Hepes pH 7.25, 0.008% NaN3, 0.65 M 
ammonium sulfate and a buffer reservoir containing 1.3 M ammonium sulfate, 20 mM Hepes 
pH 7.59. 
 
Figure 2. DAUDA binding function of ZAG. Fluorescence emission spectra at the 
excitation wavelength of 345 nm of 1 μM DAUDA in PBS and Hepes buffers upon 
sequential additions of A, B ZAG and C albumin (HSA). D, The binding curves of DAUDA 
with ZAG in PBS and Hepes buffers, and of albumin in PBS buffer. E, Fluorescence 
emission spectra of a pre-formed 0.9 µM DAUDA:0.87 µM ZAG complex upon sequential 
additions of docosahexaenoic acid (DHA) in PBS. All fluorescence spectra were corrected 
for the effects of dilution and solvent Raman scattering. F, The binding curve representing 
ZAG:DHA complex formation.  
 
Figure 3. The ZAG:DAUDA asymmetric unit and crystal packing A, The 
crystallographic ZAG:DAUDA asymmetric unit contained six ZAG and eight DAUDA 
molecules. Six DAUDA molecules were bound at the ZAG α1-α2 domain binding groove. 
The remaining two DAUDA molecules were associated with the α3 domains of chains A and 
B. B, Rotation of the ZAG:DAUDA asymmetric unit by 45° and display of symmetry 
equivalent molecules revealed β-barrel structures within the crystal lattice, formed from the 
association of four chain A α3 domains (lower), four chain B α3 domains (upper) and four α3 
domains from chains C, D, E and F. Four DAUDA molecules were located inside the chains 
AAAA and BBBB β-barrel structures while the chains CDEF β-barrel was empty.  
 
Figure 4. The fitted electron densities of DAUDA and movement of the ZAG groove.  
From left to right: A, Electron density from a composite omit map for three DAUDA 
molecules located in chains B and C, the superimposition of chains B and C and their three 
DAUDA molecules (black, dark grey, and light grey), a close-up view of the α1-α2 domain 
binding groove from chains B showing residues involved in co-ordinating DAUDA (red and 
blue), and a lateral view of the ZAG groove chain B (light grey). B, Electron density fits for 
DAUDA located in chains E and F, the superimposition of chains E and F and their 
corresponding DAUDA molecules (dark grey), a close-up view of the DAUDA binding 
pocket in chain F and highlighting residues involved in ZAG-DAUDA co-ordination (red and 
blue), and a lateral view of the groove of chain E to show the extension of the DAUDA 
carboxylic acid group out of the groove. C, The electron density fit for DAUDA located in 
chain D, the superimposition of chains A and D, a close-up view of the α1-α2 domain binding 
groove from chains D showing residues involved in co-ordinating DAUDA (red and blue) 
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and a lateral view of the groove of chain D to show the extension of the DAUDA carboxylic 
acid group out of the groove. Electron densities were generated from a composite ZAG-
DAUDA omit map contoured to 1.0σ.  
 
Figure 5. LigPlot interaction analyses of DAUDA with ZAG. DAUDA and non-ligand 
residues are shown in ball and stick representations. Hydrogen bonds are represented by 
dashed green lines with bond lengths shown in Angstroms. Hydrophobic contacts are 
represented by the red arcs with spokes pointing towards the ligand atoms they contact. In the 
LigPlot interactions of α1α2 Chain B, 11d303 denotes one of the DAUDA molecules linking 
chains B and C. 
 
Figure 6. The locations of the eight DAUDA molecules in ZAG A, Four DAUDA 
molecules were associated with chains B and C (pink), where two DAUDA link the α1-α2 
domains of chains B and C, one DAUDA was located in the α1-α2 domain groove of chain 
B, and the fourth DAUDA was associated with the α3 domain of chain B. B, Two DAUDA 
molecules are associated with chains A and D (yellow). One was buried in the α1-α2 domain 
binding groove of chain D while the second was associated with the α3 domain of chain A. 
C, Chains E and F (blue) each contained one DAUDA bound within the α1-α2 domain 
binding groove.  
 
Figure 7. Distinct DAUDA binding sites in the ZAG groove. A, B, C, Views of four ZAG 
α1-α2 domain binding grooves (chains B, E, F and D), each of which contained a single 
bound DAUDA molecule. The positions of each DAUDA molecule (light and dark grey) are 
shown relative to groove residues Y14, F77, I76, Y154, Y161 and R73 (yellow). Sidechains 
highlighted in yellow denote those that abrogate DAUDA binding to ZAG when mutated to 
alanine, as previously shown [31]. D, Superimposition of chains B, E, F and D and their 
corresponding DAUDA molecules highlighting the two different positions of four DAUDA 
molecules bound within the ZAG groove. E, The two binding conformations of polyethylene 
glycol (PEG: grey/orange) in baculovirus-expressed ZAG (PDB code: 1T7V) and seminal 
ZAG-prolactin inducible protein (PIP) complex (PDB code: 3ES6). F, Views of the ZAG 
grooves of chains B and C and highlighting the positions of two DAUDA molecules (grey 
and dark grey) that cross-link the grooves of chains B and C. 
 
Figure 8. Sedimentation velocity of ZAG with C11 DAUDA in PBS and Hepes buffer. 
Multiwavelength absorbance sedimentation data and boundary fits are shown for the 6.2 µM 
1:1 ZAG:DAUDA complex in A, B, PBS and D, E, Hepes buffer at wavelengths of 280 nm 
(protein) and 335 nm (DAUDA). For clarity only every fifth scan is shown in the fitted data 
plots. These resulted in the sedimentation coefficient c(s) distribution analyses of 6.2 µM 
ZAG, 1:1 ZAG:DAUDA and 1:10 ZAG: DAUDA complexes at 280 nm and 335 nm in C 
PBS and F Hepes buffer respectively. Two further sedimentation data and boundary fits at 
high concentration are shown for G 155 µM apo-ZAG and H, 155 µM 1:1.6 ZAG:DAUDA 
complex in 20 mM Hepes, 137 mM NaCl buffer using interference optics. For clarity only 
every second scan is shown in the fitted data plots. I, The sedimentation coefficient c(s) 
distribution analyses of 155 µM ZAG (black) and 1:1.6 ZAG:DAUDA complex (blue) in 20 
mM Hepes, 137 mM NaCl buffer. The sedimentation coefficient (S) values plotted in I were 
not corrected for buffer viscosity and density which were altered upon addition of DAUDA. 
When corrections for changes in buffer viscosity and density are included the s20,w values for 
apo ZAG and ZAG:DAUDA are very similar (Table 3). In panels C, F and I, M denotes 
monomer, D denotes dimer and T denotes tetramer. 
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Figure 9. Summary of the ZAG-DAUDA, ZAG-PIP and glycosylated plasma ZAG 
crystal structures. A, side-on view of chain B of ZAG to show four DAUDA molecules 
bound to this. The three DAUDA molecules in the α1-α2 groove  and one associated with the 
α3 domain of chain B are indicated as orange spheres. The DEBA β-sheet in the α3 domain 
is denoted as lettered, with the GFC β-sheet behind this as viewed. B, the same side-on view 
is shown for the ZAG-PIP complex (PDB code 3ES6). C, the same side-on view is shown for 
human plasma ZAG (PDB code 1ZAG) which is glycosylated at Asn89 and Asn108 on the 
α1-α2  groove and Asn239 on the α3 domain.  
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